CNS Pharmaceuticals, Inc., a preclinical stage pharmaceutical company, focuses on the development of anti-cancer drug candidates for the treatment of
primary and metastatic brain, and central nervous system tumors. Its lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma. The company was founded in 2017 and is based in Houston, Texas. The company trades on NASDAQ exchange. The company headquarter is located in Houston, TX. The company was established in the 2017.
| Ticker | CNSP |
| Long Name | CNS Pharmaceuticals, Inc. |
| Short Name | CNS Pharmaceuticals |